Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-κB control

Abstract

RelB is an unusual member of the Rel/NF-κB family of transcription factors which are involved in oncogenic processes. Due to a relaxed control by the IκBs, the cytosolic NF-κB inhibitors, RelB is constitutively expressed in the nuclei of lymphoid cells. We show here that RelB is inducibly degraded upon activation of T cells in a fashion similar to the IκBs. However, RelB degradation differs from that of IκBs since it is not induced by TNFα but only by T cell receptor or TPA/ionomycin stimulation. Moreover, RelB degradation occurs in three steps: (i) after stimulation RelB is rapidly phosphorylated at amino acids Thr84 and Ser552 followed by (ii) an N-terminal cut and, finally, (iii) the complete degradation in the proteasomes. Since mutation of the two phosphoacceptor sites to non-acceptor sites abolished RelB phosphorylation in vivo and led to the stabilization of the mutated RelBDM, site-specific phosphorylation appears to be a necessary prerequisite for RelB degradation. RelB is a crucial regulator of NF-κB-dependent gene expression. Thus, the signal-induced degradation of RelB should be an important control mechanism of NF-κB activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 3
Figure 2
Figure 4

Similar content being viewed by others

References

  • Baldwin Jr AS . 1996 Annu. Rev. Immunol. 14: 649–683

  • Barton D, HogenEsch H, Weih F . 2000 Eur. J. Immunol. 30: 2323–2332

  • Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U . 1995 Science 267: 1485–1488

  • Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D . 1995 Nature 373: 531–536

  • Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T . 1995 Genes Dev. 9: 1586–1597

  • DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M . 1996 Mol. Cell. Biol. 16: 1295–1304

  • Dobrzanski P, Ryseck RP, Bravo R . 1993 Mol. Cell. Biol. 13: 1572–1582

  • Dobrzanski P, Ryseck RP, Bravo R . 1994 EMBO J. 13: 4608–4616

  • Ghosh S, May MJ, Kopp EB . 1998 Annu. Rev. Immunol. 16: 225–260

  • Gilmore TD, Koedood M, Piffat KA, White DW . 1996 Oncogene 13: 1367–1378

  • Hibi M, Lin A, Smeal T, Minden A, Karin M . 1993 Genes Dev. 7: 2135–2148

  • Karin M, Ben-Neriah Y . 2000 Annu. Rev. Immunol. 18: 621–663

  • Lernbecher T, Muller U, Wirth T . 1993 Nature 365: 767–770

  • Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, Schimpl A, Serfling E . 1997 Eur. J. Immunol. 27: 1601–1609

  • Neumann M, Grieshammer T, Chuvpilo S, Kneitz B, Lohoff M, Schimpl A, Franza Jr BR, Serfling E . 1995 EMBO J. 14: 1991–2004

  • Neumann M, Marienfeld R, Serfling E . 1997 Int. J. Oncol. 11: 1335–1347

  • Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M . 1997 Cell 90: 373–383

  • Ryseck RP, Bull P, Takamiya M, Bours V, Siebenlist U, Dobrzanski P, Bravo R . 1992 Mol. Cell. Biol. 12: 674–684

  • Suhasini M, Reddy CD, Reddy EP, DiDonato JA, Pilz RB . 1997 Oncogene 15: 1859–1870

  • Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, Kaneko Y, Nimura Y, Motoyama N, Ikeda K, Karin M, Nakanishi M . 2000 Nature 404: 778–782

  • Weih F, Carrasco D, Bravo R . 1994 Oncogene 9: 3289–3297

  • Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, Bravo R . 1995 Cell 80: 331–340

  • Xia Y, Chen S, Wang Y, Mackman N, Ku G, Lo D, Feng L . 1999 Mol. Cell. Biol. 19: 7688–7696

Download references

Acknowledgements

We thank I Pietrowski and H Wecklein for excellent technical assistance. For critical reading of the manuscript we are indebted to Drs A Avots, S Klein-Hessling, A Schimpl, A Wilisch-Neumann and T Wirth. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) (NE 608/1-3 and 608/2-2 to M Neumann) and the Wilhelm-Sander Stiftung.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manfred Neumann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marienfeld, R., Berberich-Siebelt, F., Berberich, I. et al. Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-κB control. Oncogene 20, 8142–8147 (2001). https://doi.org/10.1038/sj.onc.1204884

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204884

Keywords

This article is cited by

Search

Quick links